Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Multicenter retrospective study of 344 pts w/ plasmablastic lymphoma finds median OS 5.0 yrs, PFS 1.4; HIV pts had best outcomes, organ transplant pts had worst; higher intensity chemo and PIs did not show survival benefit.”
Title: Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study
Authors: Matthew Hamby, Brian L. Egleston, Zachary A. K. Frosch, Raphael E. Steiner, Ariela Noy, Veronica Carvajal, Emeline R. Chong, Seda S. Tolu, Gaston Jean-Louis, Jennifer E. Amengual, Romil Patel, Sairah Ahmed, John Sharp, Timothy Voorhees, Robert Baiocchi, Andres Ramirez-Gamero, Jorge J. Castillo, Emily Hamburger, Christopher Dittus, Imran A. Nizamuddin, Neha Mehta-Shah, Nyein Nyein Thaw Dar, Jose Sandoval-Sus, Alexandra E. Rojek, Peter A. Riedell, Niloufer Khan, Alexey Danilov, Vinod Solipuram, Paul G. Rubinstein, Anthony Ariotti, Gita Suneja, Alexander Vartanov, Charles Milrod, Adam J. Olszewski, Gordon Smilnak, Emily Ayers, Sahaj Desai, Joanna M. Rhodes, Gabriella Magarelli, Tatyana Feldman, Meredith Pellon, David M. Aboulafia, William Bae, Carlos Galvez, Vineel Bhatlapenumarthi, Mehdi Hamadani, Stefan K. Barta
You can read the Full Article in Blood Cancer Journal.
You can find other articles featuring Robert Orlowski on OncoDaily.
